NRDC, Ridhi Sidhi Medicare ink pact for commercialisation of ayurvedic products

Our Bureau Hyderabad | Updated on January 11, 2018 Published on May 02, 2017

NRDC and Ridhi Sidhi Medicare, Delhi have entered into a licence agreement for the commercialisation of a slew of ayurvedic products for the management of diabetes and arthritis.

Ayush 82, an ayurvedic formulation for the management of diabetes, Ayush SG for rheumatoid arthritis and herbal product for anti-arthritis, are the products that would be marketed.

Both Ayush 82 and Ayush SG have been developed by the Central Council for Research in Ayurvedic Sciences (CCRAS), New Delhi, an autonomous organisation under the Ministry of Ayush. The herbal formulation for anti-arthritis has been developed at CSIR-NEIST, Jorhat, Assam.

These three pacts were inked by H Purushotham, Chairman & Managing Director, on behalf of National Research Development Corporation, and Shikha Garg, Proprietress, Ridhi Sidhi Medicare, at CSIR, New Delhi in the presence of the Minister of Science and Technology & Earth Sciences, Harsh Vardhan, and Girish Sahni , Director General, CSIR & Secretary, DSIR.

The NRDC chief said the corporation has so far licensed 20 ayurvedic/herbal technologies developed by CCRAS and CSIR to more than 40 companies in the country. It was the first time that a woman entrepreneur had come forward to boldly take three technologies and commercialise them from the corporation, he added.

Published on May 02, 2017
This article is closed for comments.
Please Email the Editor